Core Viewpoint - The company, Kubo Medical-B (02216), has announced a subscription agreement to issue 105 million shares at a price of HKD 3.11 per share, which represents a premium over the market price on the announcement date [1] Summary by Relevant Categories Subscription Agreement - The company has conditionally agreed to issue a total of 105 million subscription shares [1] - The subscription price of HKD 3.11 per share is approximately 1.3% higher than the closing price of HKD 3.07 on the Hong Kong Stock Exchange on the announcement date [1] - The total number of shares to be issued represents about 16.60% of the enlarged issued share capital of the company, assuming no changes in the issued share capital until completion [1] Financial Implications - The estimated net proceeds from the subscription, after expenses, are approximately HKD 327 million, equating to a net issue price of about HKD 3.106 per share [1] - The net proceeds are intended to fund potential acquisitions in the medical device industry to continuously expand the product portfolio [1]

Share Issuance - On October 9, the company issued 669,493 new shares due to employees exercising the 2023 stock option plan at an exercise price of HKD 320.63 per share [1] - The total share capital increased from 9,153,003,220 shares to 9,153,672,713 shares [1] Share Buyback - The buyback period lasted from September 24 to October 9, totaling 10 trading days [1] - A total of 8,397,000 shares were repurchased, representing approximately 0.092% of the issued shares [1] - The buyback price ranged from HKD 641.65 to HKD 677.70 per share, with a single-day buyback on October 9 of 816,000 shares costing HKD 551 million [1] Buyback Authorization Status - The buyback authorization was approved on May 14, 2025 [1] - A total of 6,989,000 shares have been repurchased, accounting for 0.76% of the shares issued at the time of authorization [1] - There is a suspension period for new share issuance for 30 days following the buyback, lasting until November 8 [1]

Core Viewpoint - Neway Group (01686) announced the issuance of a total of 41,000 shares due to the exercise of stock options [1] Group 1 - The company has issued a total of 41,000 shares as a result of stock option exercises [1]

Core Viewpoint - China Financial Leasing (02312) has entered into a subscription agreement for the conditional subscription of 69.3795 million shares at a price of HKD 1.25 per share, which represents a discount of approximately 2.34% compared to the closing price of HKD 1.28 on October 3, 2025 [1] Group 1 - The total number of shares issued by the company as of the announcement date is 347 million [1] - The subscribed shares represent approximately 20% of the total shares issued as of the announcement date and approximately 16.67% of the total shares after the issuance of the subscribed shares, assuming no other changes in share capital from the announcement date to the completion date [1] - The expected total amount raised from the subscription is approximately HKD 86.7244 million, with a net amount of approximately HKD 86.4744 million [1]

Core Viewpoint - China Financial Leasing (02312) has entered into a conditional subscription agreement to issue 69.3795 million shares at a subscription price of HKD 1.25 per share, representing a discount of approximately 2.34% from the closing price of HKD 1.28 on October 3, 2025 [1] Summary by Sections Subscription Agreement - The subscription agreement was signed on October 5, 2025, with the subscriber agreeing to conditionally subscribe for shares [1] - The total number of shares to be issued is 69.3795 million [1] Share Capital and Ownership - As of the announcement date, the company has issued 347 million shares [1] - The newly issued shares will represent approximately 20% of the total shares already issued as of the announcement date and about 16.67% of the total shares after the issuance, assuming no other changes in share capital [1] Financial Implications - The expected total proceeds from the subscription are approximately HKD 86.7244 million, with a net amount of approximately HKD 86.4744 million [1]

Core Viewpoint - China Gas (08246) announced a conditional subscription agreement to issue a total of 334 million subscription shares at a price of HKD 0.075 per share, which represents a premium of approximately 1.35% over the market closing price on the agreement date [1] Summary by Relevant Sections Subscription Details - The subscription shares represent approximately 7.83% of the existing issued share capital as of the announcement date and approximately 7.26% of the enlarged issued share capital after the issuance [1] - The total expected proceeds from the subscription are estimated to be HKD 25.05 million, with a net amount of approximately HKD 24.75 million after deducting all related expenses [1] Use of Proceeds - The net proceeds from the subscription are intended to be used for the general working capital of the group [1]

Core Points - The company announced that all conditions precedent under Share Purchase Agreement I and Share Purchase Agreement II have been fulfilled, and the agreements were completed on October 2, 2025 [1] - A total of 2.753 billion shares were issued as consideration shares [1] - The company received a conversion notice from bondholders to fully exercise their conversion rights under the convertible bond, converting HKD 1.086 billion principal amount into 5.173 billion conversion shares at a conversion price of HKD 0.21 per share [1] - After completing the necessary administrative procedures for the issuance of conversion shares, the company issued 5.173 billion conversion shares to bondholders on October 2, 2025, which rank equally with all other existing shares [1]

智通财经APP讯，创梦天地(01119)发布公告，于2025年9月29日，公司及深圳创梦与资本化协议认购人 (PLR Worldwide Sales Limited)订立资本化协议，据此，资本化协议认购人已有条件同意认购，而公司已 有条件同意按每股认购股份1.098港元的发行价向资本化协议认购人配发及发行1.66亿股认购股份，以抵 销深圳创梦对资本化协议认购人的特许权使用费。 于2025年9月29日，公司与各认购协议认购人订立认购协议，据此，各认购协议认购人已有条件同意认 购，而公司已有条件同意按每股认购股份1.098港元的发行价向各认购协议认购人配发及发行合共 6977.56万股认购股份。 认购事项的所得款项总额将约为7661万港元，其中估计所得款项净额约为7633万港元。公司拟将认购事 项的所得款项净额用于游戏产品的运营推广支出及一般营运资金。 认购价为每股认购股份1.098港元，相较于9月29日收市价每股1.050港元溢价约4.57%。假设除资本化事 项及认购事项外，公司的已发行股本自本公告日期起至资本化事项及认购事项完成之日止并无其他变 动，资本化协议及认购协议项下的认购股份相当于公司于本公告日期的现 ...

创梦天地(01119)发布公告，于2025年9月29日，公司及深圳创梦与资本化协议认购人(PLR Worldwide Sales Limited)订立资本化协议，据此，资本化协议认购人已有条件同意认购，而公司已有条件同意按每 股认购股份1.098港元的发行价向资本化协议认购人配发及发行1.66亿股认购股份，以抵销深圳创梦对资 本化协议认购人的特许权使用费。 于2025年9月29日，公司与各认购协议认购人订立认购协议，据此，各认购协议认购人已有条件同意认 购，而公司已有条件同意按每股认购股份1.098港元的发行价向各认购协议认购人配发及发行合共 6977.56万股认购股份。 认购事项的所得款项总额将约为7661万港元，其中估计所得款项净额约为7633万港元。公司拟将认购事 项的所得款项净额用于游戏产品的运营推广支出及一般营运资金。 认购价为每股认购股份1.098港元，相较于9月29日收市价每股1.050港元溢价约4.57%。假设除资本化事 项及认购事项外，公司的已发行股本自本公告日期起至资本化事项及认购事项完成之日止并无其他变 动，资本化协议及认购协议项下的认购股份相当于公司于本公告日期的现有已发行股本(不包括 ...

Group 1 - The company, Baijin Life Sciences (01466), announced a subscription agreement on September 29, 2025, to issue a total of 40 million shares at a subscription price of HKD 0.48 per share [1] - The subscription price represents a discount of approximately 14.29% compared to the closing price of HKD 0.56 per share on the Hong Kong Stock Exchange on the same date [1] - The net proceeds from the subscription are approximately HKD 19.1 million, which will be used for the company's general working capital [1]